Cyclin D 1 is frequently overexpressed in several cancers of diverse histological origin including those of the breast. However, how the overexpression of cyclin D1 contributes materially to the development of breast cancer is not understood. Two activities have been described for cyclin D1. In one, cyclin D1 together with its catalytic partners, cdk4 and cdk6, affects the activity of the retinoblastoma protein, pRb. In the other, cyclin D 1 influences the activity of a number of transcription factors without the participation of cdks. Recently, analyses of the expression patterns of thousands of genes across hundreds of human tumor specimens suggest that overexpressed cyclin D 1 engages a cdk-independent transcriptional program in human cancer. Further, these analyses suggest the involvement of the transcription factor, C/EBP, in the regulation of the genes affected by cyclin D1 in human cancer. The broad objective of the proposed research is to test the hypothesis that overexpression of cyclin DI aberrantly alters the differentiation program of mammary epithelial cells in a C/EBP-dependent manner and that its ability to do so underlies its oncogenic actions in the mammary gland. An effort will be made to understand how cyclin D1 influences the activity of C/EBP using molecular, genetic and biochemical approaches. Whether overexpression of cyclin D1, in a manner similar to aberrant expression of C/EBP, adversely alters the differentiation program of mammary epithelial cells will be determined. An attempt to develop a robust cyclin D l-dependent transformation assays using a cooperating oncogene will be made. These assays will be used to assess the contribution of the ability of cyclin D1 to aberrantly influence the activity of C/EBP_ to the transformation of mammary epithelial cells both in vitro and in vivo.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA080111-09
Application #
7342480
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-02-01
Budget End
2008-01-31
Support Year
9
Fiscal Year
2007
Total Cost
$318,438
Indirect Cost
Name
Whitehead Institute for Biomedical Research
Department
Type
DUNS #
120989983
City
Cambridge
State
MA
Country
United States
Zip Code
02142
Xiao, Tengfei; Li, Wei; Wang, Xiaoqing et al. (2018) Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy. Proc Natl Acad Sci U S A 115:7869-7878
Zhang, Jinfang; Bu, Xia; Wang, Haizhen et al. (2018) Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature 553:91-95
Li, Andrew G; Murphy, Elizabeth C; Culhane, Aedin C et al. (2018) BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1? activation. Proc Natl Acad Sci U S A 115:E9600-E9609
Wu, Yanming; Zhang, Zhao; Cenciarini, Mauro E et al. (2018) Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ER?-GREB1 Transcriptional Axis. Cancer Res 78:671-684
Witwicki, Robert M; Ekram, Muhammad B; Qiu, Xintao et al. (2018) TRPS1 Is a Lineage-Specific Transcriptional Dependency in Breast Cancer. Cell Rep 25:1255-1267.e5
Jeselsohn, Rinath; Bergholz, Johann S; Pun, Matthew et al. (2018) Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations. Cancer Cell 33:173-186.e5
Hinohara, Kunihiko; Wu, Hua-Jun; Vigneau, Sébastien et al. (2018) KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance. Cancer Cell 34:939-953.e9
Wan, Lixin; Xu, Kexin; Wei, Yongkun et al. (2018) Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function. Mol Cell 69:279-291.e5
Bierie, Brian; Pierce, Sarah E; Kroeger, Cornelia et al. (2017) Integrin-?4 identifies cancer stem cell-enriched populations of partially mesenchymal carcinoma cells. Proc Natl Acad Sci U S A 114:E2337-E2346
Hydbring, Per; Wang, Yinan; Bogorad, Roman L et al. (2017) Identification of cell cycle-targeting microRNAs through genome-wide screens. Cell Cycle 16:2241-2248

Showing the most recent 10 out of 136 publications